Investigating the Kallikrein-kinin System in Septic Cardiomyopathy
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Tongji Hospital · NCT06080282
This study is trying to see how certain molecules in the body are different in people with septic cardiomyopathy to better understand this condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 640 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Tongji Hospital (other) |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06080282 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the differential expressions of molecules in the kallikrein-kinin system (KKS) pathway among patients with septic cardiomyopathy. It will involve a prospective case-control design, collecting clinical data and blood samples over a three-year period. The study will utilize established diagnostic criteria for sepsis and septic cardiomyopathy to identify eligible participants and analyze gene expression changes related to the KKS. The findings may provide insights into the regulatory mechanisms involved in septic cardiomyopathy.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years diagnosed with septic cardiomyopathy.
Not a fit: Patients with significant underlying cardiovascular diseases or other organ dysfunctions unrelated to myocardial injury may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of septic cardiomyopathy and lead to improved diagnostic and therapeutic strategies for affected patients.
How similar studies have performed: While the specific approach of this study may be novel, similar studies investigating the role of molecular pathways in sepsis have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: (1) Age range greater than 18 years. (2) Patients diagnosed with septic cardiomyopathy. (3) Clear determination of the cause of myocardial injury, such as the source of infection, bacterial culture results, etc. (4) Patients who are capable of cooperating and completing the necessary examinations and treatments. - Exclusion Criteria: (1) Presence of other significant underlying cardiovascular diseases, such as coronary heart disease, heart failure, etc. (2) Presence of other organ dysfunction that poses a significant threat to life, such as respiratory failure, liver failure, etc. (3) Presence of severe infections or inflammatory diseases unrelated to myocardial injury, such as severe acute pancreatitis. (4) History of receiving interventional treatments, such as immunomodulatory agents, anti-inflammatory drugs, etc. (5) Pregnant or lactating women. (6) Pediatric patients who are under the age of majority. -
Where this trial is running
Wuhan, Hubei
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (RECRUITING)
Study contacts
- Principal investigator: QIN Zhang, phd — Tongji Hospital
- Study coordinator: QIN Zhang, phd
- Email: qzhang8@tjh.tjmu.edu.cn
- Phone: 15717154768
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sepsis, sepsis, Septic cardiomyopathy, KKS